Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Lysogene    LYS   FR0013233475

LYSOGENE

(LYS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
02/20/2020 02/21/2020 02/24/2020 02/25/2020 02/26/2020 Date
3.01(c) 2.83(c) 2.51(c) 3.6(c) 3.53 Last
179 489 214 561 316 909 1 703 014 145 713 Volume
-6.52% -5.98% -11.31% +43.43% -1.94% Change
More quotes
Financials (EUR)
Sales 2019 11,0 M
EBIT 2019 -4,26 M
Net income 2019 -4,77 M
Finance 2019 18,5 M
Yield 2019 -
Sales 2020 6,00 M
EBIT 2020 -12,0 M
Net income 2020 -12,3 M
Debt 2020 6,64 M
Yield 2020 -
P/E ratio 2019 -10,2x
P/E ratio 2020 -3,93x
EV / Sales2019 2,76x
EV / Sales2020 9,25x
Capitalization 48,9 M
More Financials
Company
Lysogene is a biotechnology company specializing in the research and development of gene therapies for the treatment of rare neurodegenerative diseases. The company now has 2 products in development phase for the treatment of Sanfilippo syndrom and gangliosidosis. 
More about the company
Surperformance© ratings of Lysogene
Trading Rating : Investor Rating :
More Ratings
Latest news on LYSOGENE
02/25LYSOGENE : Receives FDA Fast Track Designation for LYS-SAF302 Gene Therapy in MP..
BU
02/17LYSOGENE : Reports its Cash Position as of 31 December 2019
BU
02/17LYSOGENE : 4th quarter earnings
CO
02/12LYSOGENE : annual sales release
02/11LYSOGENE : Announces Presentations at Upcoming 16th WORLDSymposium™ on Lys..
BU
01/24LYSOGENE : Announces Its Corporate Agenda For 2020
BU
01/24LYSOGENE : Provisional calendar
CO
01/07LYSOGENE : Annual Report of the Liquidity Contract Signed by Lysogene with Gilbe..
BU
2019LYSOGENE : Announces the Publication of an Article in the Scientific Journal "Mo..
BU
2019LYSOGENE : 3rd quarter earnings
CO
2019LYSOGENE : Nomination
CO
2019LYSOGENE : Half-year results
CO
2019LYSOGENE : Nomination
CO
2019LYSOGENE : 2nd quarter earnings
CO
2019LYSOGENE : Announces Workshop at National Institutes of Health (NIH) on CNS Immu..
AQ
More news
News in other languages on LYSOGENE
02/25EN DIRECT DES MARCHES : Sanofi, Renault, Engie, Coface, Lysogène, HP, Expedia..
02/25LYSOGENE : reçoit la désignation Fast Track de la FDA pour le traitement de thér..
02/17LYSOGENE : trésorerie à 26,5 millions d'euros à fin 2019
02/17STOCK MARKET PARIS : Les Etats-Unis bullent, Pékin irrigue son économie
02/17EN DIRECT DES MARCHES : Airbus, Alstom, Safran, Faurecia, Carrefour, Toyota, ..
More news
Analyst Recommendations on LYSOGENE
More recommendations
Sector news : Bio Diagnostics & Testing
03:22aNEW CHINESE BILLIONAIRES OUTPACE U.S : Hurun
RE
02/25GILEAD SCIENCES : First U.S. Testing Begins for Potential Coronavirus Treatment
DJ
02/25Regeneron Up Nearly 6%, Best Performer in the Nasdaq 100 So Far Today -- Data..
DJ
02/24J&J, Sanofi, Inovio Hunt for Coronavirus Vaccines
DJ
02/24LONZA : France's Sanofi to carve out active drug ingredients business
RE
More sector news : Bio Diagnostics & Testing
Chart LYSOGENE
Duration : Period :
Lysogene Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LYSOGENE
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Average target price 7,15  €
Last Close Price 3,60  €
Spread / Highest target 206%
Spread / Average Target 98,6%
Spread / Lowest Target -8,33%
EPS Revisions
Managers
NameTitle
Karen Pignet-Aiach Chairman & Chief Executive Officer
Stéphane Durant des Aulnois Director-Finance & Administrative
Mark Plavsic Chief Technical Officer
Sophie Olivier Chief Medical Officer
Ralph Laufer Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
LYSOGENE98.35%53
EXACT SCIENCES CORPORATION3.33%12 804
GUARDANT HEALTH, INC.7.87%7 144
GENSCRIPT BIOTECH CORPORATION2.16%4 112
IOVANCE BIOTHERAPEUTICS, INC.13.66%3 970
INVITAE CORPORATION37.01%2 040